165 related articles for article (PubMed ID: 31962372)
1. Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta-analysis.
Boyne DJ; O'Sullivan DE; Heer EV; Hilsden RJ; Sajobi TT; Cheung WY; Brenner DR; Friedenreich CM
Cancer Med; 2020 Mar; 9(5):1613-1627. PubMed ID: 31962372
[TBL] [Abstract][Full Text] [Related]
2. Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists.
Toh JWT; Mahajan H; Chapuis P; Spring K
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1297. PubMed ID: 33030308
[TBL] [Abstract][Full Text] [Related]
3. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
[TBL] [Abstract][Full Text] [Related]
5. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
Sobrero A; Grothey A; Iveson T; Labianca R; Yoshino T; Taieb J; Maughan T; Buyse M; André T; Meyerhardt J; Shields AF; Souglakos I; Douillard JY; Cervantes A
Ann Oncol; 2018 May; 29(5):1099-1107. PubMed ID: 29438451
[TBL] [Abstract][Full Text] [Related]
6. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
[TBL] [Abstract][Full Text] [Related]
7. Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy.
Ding PQ; Batra A; Xu Y; McKinnon GP; Cheung WY
Clin Colorectal Cancer; 2020 Sep; 19(3):209-218. PubMed ID: 32291245
[TBL] [Abstract][Full Text] [Related]
8. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
[TBL] [Abstract][Full Text] [Related]
9. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
[TBL] [Abstract][Full Text] [Related]
10. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
11. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Sano T; Nunobe S
Surg Today; 2020 Oct; 50(10):1197-1205. PubMed ID: 32240378
[TBL] [Abstract][Full Text] [Related]
12. Development of a Model for Predicting Early Discontinuation of Adjuvant Chemotherapy in Stage III Colon Cancer.
Boyne DJ; Brenner DR; Sajobi TT; Hilsden RJ; Yusuf D; Xu Y; Friedenreich CM; Cheung WY
JCO Clin Cancer Inform; 2020 Oct; 4():972-984. PubMed ID: 33125264
[TBL] [Abstract][Full Text] [Related]
13. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
15. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
16. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Yoshino T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Munemoto Y; Takagane A; Ishikawa H; Ishida H; Ogata Y; Oba K; Goto K; Sakamoto J; Maehara Y; Ohtsu A
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1269-1277. PubMed ID: 31549217
[TBL] [Abstract][Full Text] [Related]
17. Optimizing adjuvant therapy and survivorship care of stage III colon cancer.
Loree JM; Cheung WY
Future Oncol; 2016 Sep; 12(17):2021-35. PubMed ID: 27301775
[TBL] [Abstract][Full Text] [Related]
18. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.
Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC
J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531
[TBL] [Abstract][Full Text] [Related]
19. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
Nyrop KA; Deal AM; Shachar SS; Basch E; Reeve BB; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Reeder-Hayes KE; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Oncologist; 2019 Jun; 24(6):762-771. PubMed ID: 30552158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
